Lactate Imaging as a Tumour Biomarker

Institute of Cancer Research, United Kingdom

Status: Completed

Conditions: Cancer

Treatments: Device: Magnetic Resonance Imaging (MRI)

Study type: Observational

Funder types: Other

Identifiers

NCT01881386

13/LO/0536 CCR3939

Details and patient eligibility

About

This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect.

The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.

Enrollment: 37 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Cohort 1:lymphoma patients

• minimum lesion size of 2cm
• not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone)

Cohort 2:Colorectal patients

• metastatic disease of at least 2cm
• not pretreated

Cohort 3:Phase 1 Drug Development

• minimum lesion size at least 2cm

Cohort 4: Brain

• primary brain tumours receiving radiotherapy and temozolomide
• cerebral lymphoma receiving standard chemotherapy

Exclusion criteria

• MRI incompatible metal implants
• Claustrophobia
• Inability to tolerate a 40 minute MRI scan

Trial design

37 participants in 4 patient groups

Lymphoma

Description:

Lymphoma patients before and after receiving standard CHOP therapy

Treatment:

Device: Magnetic Resonance Imaging (MRI)

Metastatic Colorectal

Description:

Patients with metastatic colorectal cancer

Treatment:

Device: Magnetic Resonance Imaging (MRI)

Phase 1

Description:

Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration

Treatment:

Device: Magnetic Resonance Imaging (MRI)

Brain

Description:

Patients with primary brain tumours and patients with cerebral lymphoma